 Encompass Health Corporation NYSE: EHC lowered its FY22 sales guidance from 5.38 billion - 5.50 billion to 5.33 billion - 5.42 billion, below the consensus of 5.46 billion The company forecasts adjusted EBITDA of 1.01 billion - 1.05 billion from 1.02 billion - 1.07. 